Lars Wick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lars Wick has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Young
Caris Life Sciences, Phoenix, Arizona
24 shared publications - Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
24 shared publications - Bradley Robert Corr
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Colorado School of Medicine , Aurora, CO
24 shared publications - Carine Bossard
Biosplice Therapeutics Inc, TenaRx Inc
24 shared publications - Edward B. Chuong
University of Colorado Boulder
24 shared publications - Elizabeth R. Woodruff
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
24 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
In vivo body weight and PCA plot
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
In vivo body weight and PCA plot
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Raw TOP/FOP-FLASH data from Figure 1.
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Raw TOP/FOP-FLASH data from Figure 1.
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Counts per million for RNA-seq
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Counts per million for RNA-seq
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Colony Formation and Crystal Violet
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Colony Formation and Crystal Violet
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
- Open Access
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Data from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
PARP inhibitors (PARPi) have reshaped the clinical management paradigm of multiple cancers, but none more than homologous recombination–deficient high-grade serous carcinoma (HGSC) of tubo-ovarian origin. In patients with HGSC that harbor BRCA1/2-mutations, PARPi maintenance therapy after first-line chemotherapy has resulted in significantly prolonged progression-free and overall survival. However, PARPi resistance is a major clinical challenge, and subsequent therapeutic options for patients with resistant disease remain limited. Whereas mechanisms of PARPi therapy have been described, there have been few clinical studies to translate these strategies into overcoming resistance. Elevated WNT signaling and T-cell factor (TCF) transcriptional activity contribute to PARPi resistance; however, directly targeting WNT signaling is challenging due to on-target adverse events. We tested an indirect WNT inhibitor, a dual CDC-like kinase and dual-specificity tyrosine phosphorylation–regulated kinase inhibitor, SM08502 (cirtuvivint), in combination with PARPi in multiple resistant HGSC models. We determined TCF transcriptional activity and differential gene expression with splicing analysis and used multispectral IHC to interrogate the tumor microenvironment. In PARPi-resistant models, SM08502 inhibits WNT/TCF transcriptional activity, reduces cell viability, and induces DNA damage. In addition, using multiple immune-compromised and immune-intact in vivo models of PARPi-resistant disease, SM08502, in combination with olaparib, significantly reduces disease progression, remodels the tumor immune microenvironment, and extends survival. Specifically, tumors treated with the SM08502/olaparib combination exhibit reduced immune-suppressive PD-1 and PD-L1 expression. This study provides strong preclinical evidence that SM08502, in combination with PARPi, may be an effective strategy to overcome PARPi resistance.Significance:PARPi resistance is a major clinical challenge. Overcoming PARPi resistance will provide patients with therapeutic options. The study shows, in the context of resistant disease, the potential of targeting CDC-like kinase/dual-specificity tyrosine phosphorylation–regulated kinase alone and in combination with PARP inhibitors.
- 5 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
PARP inhibitors (PARPi) have reshaped the clinical management paradigm of multiple cancers, but none more than homologous recombination–deficient high-grade serous carcinoma (HGSC) of tubo-ovarian origin. In patients with HGSC that harbor BRCA1/2-mutations, PARPi maintenance therapy after first-line chemotherapy has resulted in significantly prolonged progression-free and overall survival. However, PARPi resistance is a major clinical challenge, and subsequent therapeutic options for patients with resistant disease remain limited. Whereas mechanisms of PARPi therapy have been described, there have been few clinical studies to translate these strategies into overcoming resistance. Elevated WNT signaling and T-cell factor (TCF) transcriptional activity contribute to PARPi resistance; however, directly targeting WNT signaling is challenging due to on-target adverse events. We tested an indirect WNT inhibitor, a dual CDC-like kinase and dual-specificity tyrosine phosphorylation–regulated kinase inhibitor, SM08502 (cirtuvivint), in combination with PARPi in multiple resistant HGSC models. We determined TCF transcriptional activity and differential gene expression with splicing analysis and used multispectral IHC to interrogate the tumor microenvironment. In PARPi-resistant models, SM08502 inhibits WNT/TCF transcriptional activity, reduces cell viability, and induces DNA damage. In addition, using multiple immune-compromised and immune-intact in vivo models of PARPi-resistant disease, SM08502, in combination with olaparib, significantly reduces disease progression, remodels the tumor immune microenvironment, and extends survival. Specifically, tumors treated with the SM08502/olaparib combination exhibit reduced immune-suppressive PD-1 and PD-L1 expression. This study provides strong preclinical evidence that SM08502, in combination with PARPi, may be an effective strategy to overcome PARPi resistance.Significance:PARPi resistance is a major clinical challenge. Overcoming PARPi resistance will provide patients with therapeutic options. The study shows, in the context of resistant disease, the potential of targeting CDC-like kinase/dual-specificity tyrosine phosphorylation–regulated kinase alone and in combination with PARP inhibitors.
- Open Access
- 4 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
SM08502 and olaparib synergize to inhibit cell viability and promote DNA damage in olaparib-resistant cells. A, Indicated cell lines were treated for 7 days with increasing doses of both SM08502 (only treated on days 1 and 2) and olaparib (days 1 through 7). Cell viability was assessed via colony formation. The CI was calculated at all the dose combinations via CompuSyn software using the Chou–Talalay method for drug combination. B, Similar to (A), PEO1-OR and UWB1.289-OR cells were treated with several doses of olaparib and SM08502. The data were graphed via Large Language Models curve fitting, and synergy was calculated via the ZIP method. ZIP synergy score >10 was considered synergistic. C, PEO1-OR cells were treated with olaparib, SM08502, or in combination (ola + SM). Cells were fixed and used for IF against γH2ax (green) and nuclei (DAPI, blue). D, γH2ax were counted in the PEO1-OR cells. E, Same as (B) but used UWB1.289-OR cells. F, γH2ax were counted in the UWB1.289-OR cells. Error bars, SEM. Statistical test, one way ANOVA with Tukey multiple comparison correction.
- 4 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
SM08502 and olaparib synergize to inhibit cell viability and promote DNA damage in olaparib-resistant cells. A, Indicated cell lines were treated for 7 days with increasing doses of both SM08502 (only treated on days 1 and 2) and olaparib (days 1 through 7). Cell viability was assessed via colony formation. The CI was calculated at all the dose combinations via CompuSyn software using the Chou–Talalay method for drug combination. B, Similar to (A), PEO1-OR and UWB1.289-OR cells were treated with several doses of olaparib and SM08502. The data were graphed via Large Language Models curve fitting, and synergy was calculated via the ZIP method. ZIP synergy score >10 was considered synergistic. C, PEO1-OR cells were treated with olaparib, SM08502, or in combination (ola + SM). Cells were fixed and used for IF against γH2ax (green) and nuclei (DAPI, blue). D, γH2ax were counted in the PEO1-OR cells. E, Same as (B) but used UWB1.289-OR cells. F, γH2ax were counted in the UWB1.289-OR cells. Error bars, SEM. Statistical test, one way ANOVA with Tukey multiple comparison correction.